Polatuzumab vedotin
Modify Date: 2025-08-25 18:49:08
Polatuzumab vedotin structure
|
Common Name | Polatuzumab vedotin | ||
|---|---|---|---|---|
| CAS Number | 1313206-42-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Polatuzumab vedotinPolatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL)[1]. |
| Name | Polatuzumab vedotin |
|---|
| Description | Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL)[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Polatuzumab vedotin (0.3, 1, 3, 6, 12 mg/kg; i.v.; once) shows anti-tumor in a mouse tumour xenograft model of human diffuse large B‐cell lymphoma WSU‐DLCL2[2]. Animal Model: SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)[2] Dosage: 0.3, 1, 3, 6, 12 mg/kg Administration: I.v.; once Result: Showed dose-dependent tumour growth inhibition. |
| References |
| No Any Chemical & Physical Properties |